Furthermore, the observed relationship between RSPRY1 deficiency and TGF-β signaling might provide a foundation for novel targeted therapeutic strategies for patients with SEMD and other related skeletal dysplasias. This evidence concerns the gene RSPRY1 and spondyloepimetaphyseal dysplasia.